ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Treatment of psoriatic arthritis

Treatment of psoriatic arthritis
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2021 treatment recommendations for psoriatic arthritis (PsA) use a domain-based approach, but, considering that most patients present with disease in multiple domains, this treatment schema combines the recommendations for each domain to guide therapeutic decisions. Disease activity should be assessed in each of the domains and consideration given to comorbidities, previous therapies and patient preference. Standard "step-up" approaches, as well as expedited treatment routes, are indicated. Treatment efficacy and tolerability should be reevaluated periodically and treatment adjusted as appropriate. The order of the products in the boxes is sorted by mechanism of action and does not reflect guidance on relative efficacy or suggested usage. Bold text indicates a strong recommendation, standard text a conditional recommendation.

bDMARD: biologic disease-modifying antirheumatic drug; CTLA4-Ig: CTLA4–immunoglobulin fusion protein; csDMARD: conventional synthetic disease-modifying antirheumatic drug; ETN: etanercept; GC: glucocorticoid; IBD: inflammatory bowel disease; JAKi: Janus kinase inhibitor; MTX: methotrexate; PDE4i: phosphodiesterase 4 inhibitor; TNFi: TNF inhibitor.

* A conditional recommendation based on data from abstracts only.
Reproduced with permission from: Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18:465. Copyright © 2022 Springer Nature.
Graphic 142062 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟